uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease

uniQure N.V. announced positive topline data from its pivotal Phase I/II study of AMT-130 for Huntington's disease, with the high-dose demonstrating a statistically significant 75% slowing of disease progression at 36 months as measured by cUHDRS, and a 60% slowing by TFC, compared to an external control. The gene therapy, which was generally well-tolerated, also showed favorable trends in other clinical measures and reduced CSF NfL levels. uniQure plans to submit a BLA in Q1 2026, targeting a U.S. launch later that year, potentially offering a significant new treatment for this neurodegenerative disorder.

Analysis

uniQure N.V. has reported compellingly positive topline data from its pivotal Phase I/II study of AMT-130, a gene therapy for Huntington’s disease. The high-dose treatment met its primary endpoint by demonstrating a statistically significant 75% slowing of disease progression at 36 months, as measured by the cUHDRS scale (p=0.003), compared to a propensity-score matched external control. The study also achieved a key secondary endpoint, showing a 60% slowing of disease progression on the Total Functional Capacity (TFC) scale (p=0.033). These clinical outcomes are further substantiated by a reduction in cerebrospinal neurofilament light protein (CSF NfL), a key biomarker for neurodegeneration, to below baseline levels. The company noted a dose-dependent response, with the high-dose group showing consistently favorable results over the low-dose group, and a manageable safety profile with no new serious adverse events since late 2022. This data package significantly de-risks the asset and positions AMT-130 as a potential first-in-class, disease-modifying therapy for a condition with no approved treatments to slow progression. Based on these results, which were generated under a statistical plan previously aligned with the FDA, uniQure intends to submit a Biologics License Application (BLA) in the first quarter of 2026, targeting a potential U.S. launch later that year.

Key Decisions for Investors

• The highly statistically significant primary and secondary endpoint data represent a major clinical de-risking event, warranting a reassessment of uniQure's valuation to reflect a substantially increased probability of approval and commercial success for AMT-130.
• Investors should monitor key upcoming catalysts, including the outcome of the pre-BLA meeting with the FDA later this year and the BLA submission timing in Q1 2026, as these will provide critical updates on the regulatory pathway.
• While the results are strong, it is prudent to consider the risk associated with the use of an external control group rather than a randomized placebo, which could still be a point of scrutiny during the FDA's review.
• Given the lack of disease-modifying treatments for Huntington's, this data establishes a potential first-mover advantage, and focus should now shift to modeling the total addressable market and pricing for a one-time gene therapy.